Incyte | INCY

Stock Price
86.64
Daily Change
1.20 1.40%
Monthly
11.58%
Yearly
41.43%
Q3 Forecast
85.92

Peers Price Chg Day Year Date
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US500 6481 -20.59 -0.32% 19.84% Sep/05

Incyte Corp traded at $86.64 this Friday September 5th, increasing $1.20 or 1.40 percent since the previous trading session. Looking back, over the last four weeks, Incyte gained 11.58 percent. Over the last 12 months, its price rose by 41.43 percent. Looking ahead, we forecast Incyte Corp to be priced at 85.92 by the end of this quarter and at 83.80 in one year, according to Trading Economics global macro models projections and analysts expectations.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.